ALEC
Alector IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$258.80M
P/E Ratio
—
EPS
$-1.39
Beta
0.58
52W High
$3.40
52W Low
$0.87
50-Day MA
$2.09
200-Day MA
$1.98
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
8.47
PEG Ratio
—
About Alector Inc
Alector, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of neurodegenerative diseases. The company is headquartered in South San Francisco, California.
Fundamentals
| Revenue (TTM) | $21.05M |
| Gross Profit (TTM) | $-102.02M |
| EBITDA | $-147.37M |
| Operating Margin | -588.00% |
| Return on Equity | -181.60% |
| Return on Assets | -25.10% |
| Revenue/Share (TTM) | $0.20 |
| Book Value | $0.28 |
| Price-to-Book | 8.68 |
| Price-to-Sales (TTM) | 12.30 |
| EV/Revenue | 2.195 |
| EV/EBITDA | -8.40 |
| Quarterly Earnings Growth (YoY) | -86.30% |
| Quarterly Revenue Growth (YoY) | -88.50% |
| Shares Outstanding | $110.36M |
| Float | $86.31M |
| % Insiders | 10.05% |
| % Institutions | 80.78% |
Analyst Ratings
Consensus ($2.88 target)
2
Buy4
Hold1
Sell1
Strong SellData last updated: 4/7/2026